People · Operator
Named in public records as an officer, director or promoter · active 2021–2026 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| OncoNano Medicine, Inc. | — | Biotechnology | Series C | $115.0M | $84.2M | 2025 |
| Altesa BioSciences, Inc. | — | Pharmaceuticals | Series C | $110.0M | $373.9M | 2022 |
| Revelar Biotherapeutics, Inc. | — | Biotechnology | Series B | $18.5M | $20.0M | 2021 |
Brett Giroir at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Brett Giroir on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ittai Harel | 1 | 6 |
| David Scheer | 1 | 6 |
| Seth Rudnick | 1 | 5 |
| Paul Fonteyne | 1 | 5 |
| Jeff Keyser | 1 | 3 |
| Ravi Srinivasan | 1 | 3 |
| Moncef Slaoui | 1 | 3 |
| John Dyett | 1 | 3 |
| Martin Driscoll | 1 | 3 |
| Alvaro Guillem | 1 | 3 |
| Laurence Smith | 1 | 2 |
| Nicholas Williams | 1 | 2 |
| Gina Jones | 1 | 2 |
| Joydeep Goswami | 1 | 2 |
| Yumin Qui | 1 | 1 |
| Kartik Krishnan | 1 | 1 |
| Melissa Paoloni | 1 | 1 |
| Yumin Qiu | 1 | 1 |
| John Clerici | 1 | 1 |
| Caleb Smith | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.